Stroke is so disappointing a disease for both neurologists and patients. In most cases, the effective managements are lacking. We prescribe aspirin, statin, and anti-hypertension treatment. A significant statistic difference in favor of these therapies can be achieved in clinical trials with large sample size, but their effects are often not observed for an individual. Recombinant tPA thrombolysis can reverse neurological deficits in some patients within hours, but only few patients have chance to accept tPA treatment due to the short time window.
How could we understand stroke practice and improve it?
